Myrobalan Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $850K

  • Investors
  • 9

Myrobalan Therapeutics General Information

Description

Operator of a therapeutic biotechnology company intended for developing oral neurorestorative therapies. The company offers neurological processes such as demyelination and neuroinflammation and innovative drug discovery tools to create selective and brain-penetrant therapeutic candidates that are positioned for addressing unmet medical needs in CNS diseases, enabling healthcare professionals to provide therapeutic opportunities for a large patient population with unmet medical needs.

Contact Information

Website
www.myrotx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 200 Boston Avenue
  • Suite G750
  • Medford, MA 02155
  • United States
+1 (857)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 200 Boston Avenue
  • Suite G750
  • Medford, MA 02155
  • United States
+1 (857)

Myrobalan Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Myrobalan Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Grant 13-Mar-2025 $850K Completed Generating Revenue
5. Grant 07-Feb-2024 Completed Generating Revenue
4. Early Stage VC (Series A) 10-Jan-2024 Completed Generating Revenue
3. Accelerator/Incubator 01-Apr-2023 Completed Generating Revenue
2. Accelerator/Incubator 01-Dec-2022 $10M Completed Generating Revenue
1. Seed Round 01-Apr-2022 $10M $10M Completed Pre-Clinical Trials
To view Myrobalan Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Myrobalan Therapeutics Patents

Myrobalan Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026213397-A1 Salt and polymorph forms of csf-1r inhibitor Pending 03-Apr-2025
WO-2025195241-A1 Gpr17 receptor inhibitor and use thereof Pending 19-Mar-2024
WO-2024217523-A1 Selective tky2 inhibitors and uses thereof Inactive 20-Apr-2023
WO-2024211708-A1 Tyk2 inhibitors for treatment of glaucoma Inactive 06-Apr-2023
AU-2023380534-A1 Gpr17 modulators and uses thereof Pending 20-Nov-2022 C07D471/04
To view Myrobalan Therapeutics’s complete patent history, request access »

Myrobalan Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Myrobalan Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Multiple Sclerosis Society (NMSS) Not-For-Profit Venture Capital
The ALS Association Not-For-Profit Venture Capital
AB Magnitude Ventures Group Venture Capital Minority
Co-Win Ventures Venture Capital Minority
Guanzi Private Equity Fund Management Growth/Expansion Minority
You’re viewing 5 of 9 investors. Get the full list »

Myrobalan Therapeutics FAQs

  • When was Myrobalan Therapeutics founded?

    Myrobalan Therapeutics was founded in 2021.

  • Where is Myrobalan Therapeutics headquartered?

    Myrobalan Therapeutics is headquartered in Medford, MA.

  • What is the size of Myrobalan Therapeutics?

    Myrobalan Therapeutics has 15 total employees.

  • What industry is Myrobalan Therapeutics in?

    Myrobalan Therapeutics’s primary industry is Drug Discovery.

  • Is Myrobalan Therapeutics a private or public company?

    Myrobalan Therapeutics is a Private company.

  • What is Myrobalan Therapeutics’s current revenue?

    The current revenue for Myrobalan Therapeutics is .

  • How much funding has Myrobalan Therapeutics raised over time?

    Myrobalan Therapeutics has raised $43M.

  • Who are Myrobalan Therapeutics’s investors?

    National Multiple Sclerosis Society (NMSS), The ALS Association, AB Magnitude Ventures Group, Co-Win Ventures, and Guanzi Private Equity Fund Management are 5 of 9 investors who have invested in Myrobalan Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process